Lactated Ringer's as a Base Solution for del Nido Cardioplegia

Unavailability of Plasma-Lyte A precludes the utility of traditional del Nido cardioplegia in many countries. This observational study aimed to evaluate myocardial preservation and clinical outcomes when using lactated Ringer's solution as the base solution for del Nido cardioplegia as compared with our institute's standard blood cardioplegia strategy. Eighty-nine adult patients underwent cardiac surgery for acquired heart disease from February 2017 to November 2017 either with del Nido cardioplegia (n = 44) or blood cardioplegia (n = 45). Clinical data and outcomes were compared. Patient characteristics were similar between groups. Troponin T release was lower in the del Nido group on postoperative day 1 (.632 [.437, .907] vs. .827 [.599, 1.388] ng/mL; p = .009) and day 2 (.363 [.250, .451] vs. .549 [.340, .897] ng/mL; p = .002). The del Nido group exhibited lower total volume of cardioplegia administered (1,075 [1,000, 1,250] vs. 3,400 [2,700, 3,750] mL; p < .0001), fewer doses (1.6 ± .7 vs. 4.6 ± 1.3; p < .0001), and a decreased incidence of ventricular fibrillation after aortic cross-clamp removal (9.09 vs. 31.11%; p = .01). The del Nido group had shorter intensive care unit stays (2 [1, 2] vs. 3 [2, 4] days; p < .0001), hospital stays (7 [6, 10] vs. 9 [7, 10] days; p = .0002), less vasopressor and inotropic support (1 [1, 1] vs. 1 [1, 2] days; p = .0001), and lower incidence of postoperative atrial fibrillation/flutter (25 vs. 46.7%; p = .033). No mortality occurred and clinical outcomes were similar. The use of traditional del Nido cardioplegia ingredients added to lactated Ringer's as the base solution provided either similar or superior myocardial protection than our blood cardioplegia strategy depending on the outcome measure analyzed. The use of lactated Ringer's as a base solution may be an option for centers that do not have access to Plasma-Lyte. Further investigation and follow-up are warranted after this observational study.